Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v2.4.0.8
Condensed Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Mar. 31, 2014
Dec. 31, 2013
Current assets:    
Cash and cash equivalents $ 6,743 $ 7,279
Marketable securities, current 65,250 58,390
Collaboration receivable 5,192 18,094
Prepaid expenses and other current assets 1,311 2,246
Total current assets 78,496 86,009
Marketable securities, non-current 14,393 16,364
Property and equipment, net 632 686
Other assets 1,159 1,059
Total assets 94,680 104,118
Current liabilities:    
Accounts payable 4,006 1,689
Accrued clinical and development expenses 5,492 7,444
Accrued liabilities 3,962 3,161
Deferred revenue, current 14,722 14,722
Total current liabilities 28,182 27,016
Warrant liability 21,964 23,421
Deferred revenue, non-current 73,235 76,916
Deferred rent 287 240
Total liabilities 123,668 127,593
Commitments and contingencies (Note 7)      
Stockholders' equity (deficit):    
Preferred stock, $0.001 par value, 2,000,000 shares authorized; no shares issued and outstanding      
Common stock, $0.001 par value, shares authorized: 150,000,000 shares; issued and outstanding: 59,346,025 shares at March 31, 2014 and 59,232,611 shares at December 31, 2013 59 59
Additional paid-in capital 329,727 328,116
Accumulated other comprehensive gain (loss) 13 28
Accumulated deficit (358,787) (351,678)
Total stockholders' equity (deficit) (28,988) (23,475)
Total liabilities and stockholders' equity (deficit) $ 94,680 $ 104,118